Tax-driven SOPHiA Genetics (NASDAQ: SOPH) insider share sale under 10b5-1 plan

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief People Officer Manuela Valente reported an open-market sale of 3,824 Ordinary Shares on April 8, 2026 at a weighted average price of $4.849 per share. According to the disclosure, the shares were sold to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026.

The filing states these sales were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After this transaction, Valente directly holds 215,451 Ordinary Shares of SOPHiA GENETICS SA.

Insider Trade Summary 10b5-1

Net Seller: 3,824 shares ($18,543)

Net Sell 1 txn

Insider Valente Manuela

Role Chief People Officer

Sold 3,824 shs ($19K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	3,824	$4.849	$19K

Holdings After Transaction: Ordinary Shares — 215,451 shares (Direct)

Footnotes (1)

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.78 to $4.94, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 3,824 shares Weighted average sale price: $4.849 per share Post-transaction holdings: 215,451 shares +2 more

5 metrics

Shares sold 3,824 shares Open-market sale on April 8, 2026

Weighted average sale price $4.849 per share Ordinary Shares sold in multiple transactions

Post-transaction holdings 215,451 shares Ordinary Shares beneficially owned after sale

Sale price range $4.78–$4.94 per share Range of transaction prices referenced in footnote

Net shares sold 3,824 shares Net sell direction in transaction summary

Key Terms

Rule 10b5-1 trading plan, restricted stock units, weighted average price, beneficially owned

4 terms

Rule 10b5-1 trading plan financial

"These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficially owned financial

"total_shares_following_transaction": "215451.0000"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valente Manuela

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/08/2026		S		3,824(1)	D	$4.849(2)	215,451	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.78 to $4.94, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Manuela Valente	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) report for Manuela Valente?

SOPHiA GENETICS reported that Chief People Officer Manuela Valente sold 3,824 Ordinary Shares on April 8, 2026. The sale was in the open market at a weighted average price of $4.849 per share, as disclosed in a Form 4 filing.

Why did SOPHiA GENETICS (SOPH) Chief People Officer sell 3,824 shares?

The 3,824 shares were sold to cover tax withholding obligations related to the vesting of restricted stock units on April 2 and 3, 2026. The filing describes these as tax-driven, non-discretionary sales rather than ordinary portfolio trading.

Was the SOPHiA GENETICS (SOPH) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sales were executed under a pre-established Rule 10b5-1 trading plan adopted by the reporting person. This indicates the trades were pre-planned and not timed at the insider’s discretion, reducing their informational significance.

How many SOPHiA GENETICS (SOPH) shares does Manuela Valente hold after the sale?

Following the reported transaction, Chief People Officer Manuela Valente directly holds 215,451 Ordinary Shares of SOPHiA GENETICS SA. This post-transaction holding is disclosed in the Form 4 as the number of shares beneficially owned after the sale.

What price range were the SOPHiA GENETICS (SOPH) shares sold at in this Form 4?

The filing reports a weighted average sale price of $4.849 per share. Footnotes explain the shares were sold in multiple transactions at prices ranging from $4.78 to $4.94, inclusive, with detailed breakdowns available upon written request.